We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

GSK plc (GSK) ADR Each Repr 2 Ord Shares GBP0.25

Sell:$33.90 Buy:$34.16 Change: $0.26 (0.77%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Ex-dividend
Sell:$33.90
Buy:$34.16
Change: $0.26 (0.77%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Ex-dividend
Sell:$33.90
Buy:$34.16
Change: $0.26 (0.77%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Ex-dividend
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Contact details

Address:
980 Great West Road
BRENTFORD
TW8 9GS
United Kingdom
Telephone:
+44 (20) 80475000
Website:
https://www.gsk.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GSK
ISIN:
US37733W2044
Market cap:
$68.34 billion
Shares in issue:
4.08 billion
Sector:
Pharmaceuticals
Exchange:
-
Country:
Great Britain
Currency:
US dollar
Indices:
n/a

Key personnel

  • Emma Walmsley
    Chief Executive Officer, Executive Director
  • Julie Brown
    Chief Financial Officer, Executive Director
  • David Redfern
    President - Corporate Development
  • Regis Simard
    President - Global Supply Chain
  • Phil Thomson
    President - Global Affairs
  • Deborah Waterhouse
    Chief Executive Officer, ViiV Healthcare and President - GSK Global Health
  • Diana Conrad
    Chief People Officer
  • James Ford
    Senior Vice President, Group General Counsel, Legal and Compliance
  • Sally Jackson
    Senior Vice President - Global Communications and CEO Office
  • Shobie Ramakrishnan
    Chief Digital and Technology Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.